Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 to 60 years of age.~* Meets Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria for schizophrenia (paranoid type, disorganized type, catatonic type, or undifferentiated type) based on a Structured Clinical Interview for DSM-IV (SCID).~* Total Positive and Negative Syndrome Scale (PANSS) score ≥ 80 and ≤ 120.~* Diagnosis of schizophrenia for at least 1 year.~Exclusion Criteria:~* Abnormalities on physical examination or abnormal vital signs, electrocardiogram, or clinical laboratory values.~* First episode of psychosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once a day for 6 weeks.
- Cariprazine 1.5 mg (Type: EXPERIMENTAL): Participants received cariprazine 1.5 mg orally once a day for 6 weeks.
- Cariprazine 3.0 mg (Type: EXPERIMENTAL): Participants received cariprazine 3.0 mg orally once a day for 6 weeks.
- Cariprazine 4.5 mg (Type: EXPERIMENTAL): Participants received cariprazine 4.5 mg orally once a day for 6 weeks.
- Risperidone 4.0 mg (Type: ACTIVE_COMPARATOR): Participants received risperidone 4.0 mg orally once a day for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).